cebranopadol (TRN-228) - Tris Pharma
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. (clinicaltrials.gov) - May 9, 2024 - P1 | N=30 | Completed | Sponsor: Tris Pharma, Inc. | Recruiting ➔ Completed | Trial completion date: Mar 2023 ➔ Jan 2024 
Trial completion • Trial completion date • Pain
http://clinicaltrials.gov/ct2/show/NCT05491785
 
May 9, 2024
 
Prev Next